Analyzing Aligos Therapeutics (NASDAQ:ALGS) & Genetic Technologies (NASDAQ:GENE)

Genetic Technologies (NASDAQ:GENE) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, dividends and profitability.

Analyst Ratings

This is a breakdown of recent ratings for Genetic Technologies and Aligos Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genetic Technologies	0	0	0	0	0.00
Aligos Therapeutics	0	0	1	0	3.00

Aligos Therapeutics has a consensus price target of $75.00, suggesting a potential upside of 134.38%. Given Aligos Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Aligos Therapeutics is more favorable than Genetic Technologies.

Volatility and Risk

Genetic Technologies has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500. Comparatively, Aligos Therapeutics has a beta of 2.5, meaning that its share price is 150% more volatile than the S&P 500.

Insider & Institutional Ownership

0.6% of Genetic Technologies shares are owned by institutional investors. Comparatively, 60.4% of Aligos Therapeutics shares are owned by institutional investors. 6.5% of Genetic Technologies shares are owned by company insiders. Comparatively, 8.8% of Aligos Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Genetic Technologies and Aligos Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Genetic Technologies	N/A	N/A	N/A
Aligos Therapeutics	-1,283.19%	-114.34%	-64.58%

Earnings & Valuation

This table compares Genetic Technologies and Aligos Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genetic Technologies	$7.66 million	0.44	-$7.88 million	N/A	N/A
Aligos Therapeutics	$15.53 million	7.40	-$87.68 million	($13.32)	-2.40

Genetic Technologies has higher earnings, but lower revenue than Aligos Therapeutics.

Summary

Aligos Therapeutics beats Genetic Technologies on 8 of the 12 factors compared between the two stocks.

About Genetic Technologies

Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people's health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates through AffinityDNA, EasyDNA, and GeneType/Corporate segments. The company offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include colorectal cancer, ovarian cancer, prostate cancer, coronary artery, type 2 diabetes, pancreatic cancer, melanoma, and atrial fibrillation. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne for the development and commercialization of a novel colorectal cancer risk assessment test; and Memorial Sloan Kettering Cancer Center of New York and University of Cambridge, that assess the conflict among BRCA mutation carriers considering preventive surgery. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.

About Aligos Therapeutics

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.